Clinical experience with linezolid in infants and children
Open Access
- 26 April 2011
- journal article
- case report
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (Supplement) , iv23-iv41
Abstract
The worldwide spread of multidrug-resistant organisms has required the development of new antimicrobials. Linezolid, the first oxazolidinone, has a broad spectrum of activity against Gram-positive bacteria, including resistant strains. Although approved by the Food and Drug Administration in 2002, the clinical experience with linezolid in the paediatric population is still limited, also given the fact that in most European countries the paediatric use of linezolid is off-label. In this paper we summarize the actual evidence on the clinical use of linezolid in children, including efficacy, safety and tolerability issues. Taking into account the potential bias in comparing heterogeneous clinical trials and reports, the available literature data suggest that linezolid is a safe and effective agent for the treatment of serious Gram-positive bacterial infections in neonates and children. At present, linezolid is reserved for those children who are intolerant to or fail conventional agents. A linezolid-containing regimen can be a valuable option for treating multidrug-resistant and extensively drug-resistant tuberculosis in children as well as disseminated non-tuberculous mycobacterial infections. Given the rare occurrence of serious side effects, careful monitoring of haematological parameters, possible drug interactions and neurological manifestations is recommended in linezolid-treated children, especially in case of prolonged treatments. Appropriate linezolid dosage and hospital infection control measures are essential to avoid the spread of linezolid resistance. Further studies are needed to establish novel paediatric indications for linezolid use and to assess the tolerability of long-term treatments.Keywords
This publication has 101 references indexed in Scilit:
- Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06Journal of Antimicrobial Chemotherapy, 2010
- Linezolid in the Treatment of Multidrug‐Resistant TuberculosisClinical Infectious Diseases, 2010
- An uncommon presentation for a severe invasive infection due to methicillin-resistant Staphylococcus aureus clone USA300 in Italy: a case reportAnnals of Clinical Microbiology and Antimicrobials, 2008
- Health Care-Associated Endocarditis Caused by Staphylococcus aureus with Reduced Susceptibility to VancomycinJournal of Clinical Microbiology, 2008
- Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case seriesDiagnostic Microbiology and Infectious Disease, 2007
- Meningitis Due toGemella haemolysansin a Pediatric CaseJournal of Clinical Microbiology, 2007
- Linezolid-induced optic neuropathy: a mitochondrial disorder?British Journal of Ophthalmology, 2006
- Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipientPediatric Nephrology, 2005
- External Cooling in the Management of FeverClinical Infectious Diseases, 2000
- Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center 1 1Edited by D. E. DraperJournal of Molecular Biology, 1999